[March 25, 2015]

Research and Markets: Allergan's Abicipar Pegol (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/zrzncg/abicipar_pegol) has announced the addition of the "Abicipar Pegol (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.

Currently the ME and AMD (News - Alert) markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class herapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Allergan's abicipar pegol is a novel, long-acting anti-VEGF drug that is based on the DARPin technology. It is undergoing clinical development as a potential treatment for patients with wAMD, and a Phase III clinical trial is expected to begin in Q2 2015.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Abicipar Pegol including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Abicipar Pegol for the top country from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Need and Opportunity

7 Pipeline Assessment

8 Abicipar pegol

9 Appendix

For more information visit http://www.researchandmarkets.com/research/zrzncg/abicipar_pegol

[ Back To TMCnet.com's Homepage ]